FDA's September 2026 Direct Final Rule on Nonclinical Testing Terminology
A Direct Final Rule updating FDA's nonclinical testing terminology would formally weave new approach methodologies (NAMs) into drug-development vocabulary; whether FDA revises the text during the comment window is the near-term question.
In September 2026, FDA issued a Direct Final Rule on Nonclinical Testing Terminology, which Foley & Lardner describes as a further step toward integrating new approach methodologies (NAMs) — non-animal tools used to assess safety and efficacy — into drug development. Because a direct final rule is published for public comment and normally takes effect unless FDA withdraws or revises it during the comment window, the first question for counsel is whether the agency amends the language rather than the date clients plan around.
Terminology rules are rarely cosmetic. Terms such as animal study, toxicology, or nonclinical safety testing recur across INDs, NDAs and BLAs, as well as promotional claims and marketing authorization files; a controlling glossary can therefore shape what data sponsors must generate and how testing is characterized in submissions. The audience spans small molecule and biologic developers, contract research organizations, and investors diligencing pipeline assets.
Next to watch: the docket and comment deadline, any FDA withdrawal or revision before the rule becomes final, and how the new definitions interact with ICH-recognized methods and the wider push to reduce animal testing. Caveat: this cluster reflects a single publisher, and the rule text is not reproduced in the available evidence, so specific definitions, scope, and timing should be confirmed against the Federal Register notice.